199 related articles for article (PubMed ID: 19090322)
1. APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia.
Rosenberg R; Seiden DJ; Hull SG; Erman M; Schwartz H; Anderson C; Prosser W; Shanahan W; Sanchez M; Chuang E; Roth T
Sleep; 2008 Dec; 31(12):1663-71. PubMed ID: 19090322
[TBL] [Abstract][Full Text] [Related]
2. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness.
Walsh JK; Salkeld L; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2010 Jan; 11(1):23-30. PubMed ID: 19945340
[TBL] [Abstract][Full Text] [Related]
3. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.
Roth T; Hull SG; Lankford DA; Rosenberg R; Scharf MB;
Sleep; 2008 Sep; 31(9):1277-84. PubMed ID: 18788653
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
[TBL] [Abstract][Full Text] [Related]
5. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y
Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.
Krystal AD; Lankford A; Durrence HH; Ludington E; Jochelson P; Rogowski R; Roth T
Sleep; 2011 Oct; 34(10):1433-42. PubMed ID: 21966075
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.
Zammit G; Erman M; Wang-Weigand S; Sainati S; Zhang J; Roth T
J Clin Sleep Med; 2007 Aug; 3(5):495-504. PubMed ID: 17803013
[TBL] [Abstract][Full Text] [Related]
8. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial.
Ivgy-May N; Ruwe F; Krystal A; Roth T
Sleep Med; 2015 Jul; 16(7):838-44. PubMed ID: 26047892
[TBL] [Abstract][Full Text] [Related]
9. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
Erman MK; Zammit G; Rubens R; Schaefer K; Wessel T; Amato D; Caron J; Walsh JK
J Clin Sleep Med; 2008 Jun; 4(3):229-34. PubMed ID: 18595435
[TBL] [Abstract][Full Text] [Related]
10. Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia.
Deacon S; Staner L; Staner C; Legters A; Loft H; Lundahl J
Sleep; 2007 Mar; 30(3):281-7. PubMed ID: 17425224
[TBL] [Abstract][Full Text] [Related]
11. A polysomnography study of eszopiclone in elderly patients with insomnia.
McCall WV; Erman M; Krystal AD; Rosenberg R; Scharf M; Zammit GK; Wessel T
Curr Med Res Opin; 2006 Sep; 22(9):1633-42. PubMed ID: 16968566
[TBL] [Abstract][Full Text] [Related]
12. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.
Mayer G; Wang-Weigand S; Roth-Schechter B; Lehmann R; Staner C; Partinen M
Sleep; 2009 Mar; 32(3):351-60. PubMed ID: 19294955
[TBL] [Abstract][Full Text] [Related]
15. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea.
Kryger M; Wang-Weigand S; Roth T
Sleep Breath; 2007 Sep; 11(3):159-64. PubMed ID: 17294232
[TBL] [Abstract][Full Text] [Related]
16. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
Roth T; Krystal A; Steinberg FJ; Singh NN; Moline M
Sleep; 2013 Feb; 36(2):189-96. PubMed ID: 23372266
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.
Walsh JK; Mayleben D; Guico-Pabia C; Vandormael K; Martinez R; Deacon S
Sleep Med; 2008 May; 9(4):393-402. PubMed ID: 17765013
[TBL] [Abstract][Full Text] [Related]
18. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
Walsh JK; Thacker S; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2009 Sep; 10(8):859-64. PubMed ID: 19345644
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
Krystal AD; Walsh JK; Laska E; Caron J; Amato DA; Wessel TC; Roth T
Sleep; 2003 Nov; 26(7):793-9. PubMed ID: 14655910
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
Krystal AD; Durrence HH; Scharf M; Jochelson P; Rogowski R; Ludington E; Roth T
Sleep; 2010 Nov; 33(11):1553-61. PubMed ID: 21102997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
